Lungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy
STARI will investigate continual diaphragm neurostimulation to improve lung, diaphragm, cardiac and brain function at the earliest stages of mechanical ventilation EXTON, PA, November 4, 2025 – Lungpacer Medical, a leader in innovative respiratory care neurostimulation technologies, today announced the first six patients enrolled in the groundbreaking STARI (STimulation to Activate RespIration) clinical trial. STARI […]
Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
Exton, PA – August 14, 2025 – Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for the AeroPace® System under the Fiscal Year 2026 Inpatient Prospective Payment System (IPPS) […]
After Tragedy, an Entrepreneur’s Triumph
Brian Gormley of the Wall Street Journal publishes article on Lungpacer’s 15-year journey from a deeply personal mission sparked by a family tragedy to groundbreaking medical innovation. Nearly 2.5 million patients in the U.S. require mechanical ventilation each year, and for many, weaning off ventilation can be a struggle. Sadly, some never do. Research shows […]
American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System’s Breakthrough Results in Ventilator Weaning
International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by 3 days in patients difficult to wean from mechanical ventilation EXTON, PA, June 12, 2025 – Lungpacer Medical, Inc., a pioneering medical device company focused on neurostimulation therapies for critical care patients, today announced the […]
Lungpacer Medical to Present Innovative Research at ATS 2025
Timothy Alexander of MyChesCo publishes article about Lungpacer’s upcoming research presentations at the American Thoracic Society (ATS) 2025 conference in San Francisco, California.
April 2025 | Cardiovascular Research Foundation THT | Diaphragm Neurostimulation to optimize Biventricular Performance during Invasive Mechanical Ventilation for Acute Respiratory Failure
Lungpacer Medical Names Kevin Kearney as Chief Commercial Officer
Timothy Alexander of MyChesCo publishes article about Lungpacer Medical hiring Kevin Kearney as CCO, to lead the commercialization effort of its FDA-approved AeroPace® System.
To Prep for First Product Launch, Exton’s Lungpacer Medical Doubles Workforce
Leah Mikulich at DELCO.TODAY publishes article about Lungpacer Medical’s anticipated growth for the commercial launch of its AeroPace® System after receiving FDA approval earlier this year.
Lungpacer wins FDA IDE for AeroNova system
Sean Whooley at MassDevice publishes article about Lungpacer Medical’s receipt of an FDA investigational device excemption (IDE) to begin a clinical trial for its AeroNova System.
Lungpacer announces participation and presentation at the LSI USA 2024 Conference
From LSI: “Lungpacer Medical (hashtag#LSIUSA24 Innovator) has designed the AeroPace® System to stimulate the nerves that activate the diaphragm muscle to rebuild diaphragm strength and shorten the time on mechanical ventilation for critical care patients. Over a third of ventilated patients in ICUs require more than 4 days of mechanical ventilation. Studies have shown that […]